Contrea wins Mizuho Innovation Award, secures debt financing from Mizuho Bank
What's the deal? ContreaDealroom has a profile for this one. Try Dealroom →, a Tokyo-based startup that builds a patient-communication platform called MediOS, has won the Mizuho Innovation Award for Q3 2025 and secured debt financing from Mizuho BankDealroom has a profile for this one. Try Dealroom →. The company plans to use the funds to strengthen its product, grow its team, and develop new business lines.
Founded in 2020 by Kazuhiro KawabataDealroom has a profile for this one. Try Dealroom → — a former radiological technologist — Contrea digitises the back-and-forth between doctors and patients. MediOS handles patient explanations, intake questionnaires, consent collection, and follow-up calls, replacing paper-heavy workflows so clinicians can focus on care.
The Mizuho Innovation Award, launched in 2017, is a quarterly programme that recognises promising startups based on business-model strength, team capability, and growth potential. Winners receive business-matching support with large corporates.
Why now? Japan faces a deepening healthcare labour shortage compounded by a rapidly ageing population. Hospitals need tools that let fewer staff serve more patients without sacrificing quality. Mizuho noted that MediOS addresses both sides of this equation — boosting clinician efficiency while improving patient comprehension.
"I saw many patients go into treatment still anxious because explanations hadn't landed," Kawabata said, describing his motivation from his years on the hospital floor.
What could go wrong? The specific loan amount was not disclosed, which makes it hard to gauge how far the capital will stretch. Healthcare software adoption in Japan can be slow; hospitals are notoriously conservative about changing established processes. Contrea will also need to prove it can scale across diverse medical institutions with different workflows and legacy systems.
The signal: Contrea sits at the early growth stage, and opting for debt rather than dilutive equity suggests the company already generates enough recurring revenue to service a loan — a relative rarity for Japanese healthtech startups at this phase. Mizuho's backing, as a corporate investor that pairs financing with large-enterprise matchmaking, could prove more valuable than the capital itself by opening doors to hospital networks the startup would struggle to reach on its own.
Read more: prtimes.jp
